I have been prescribed ozanimod
Important Contact Information

My healthcare professional who prescribed ozanimod:

Name: _____

Office phone number: _____

Institution address: _____

_____

2084-IL-2500006

This card and its content have been approved by the Ministry of Health in June 2025

ZEPOSIA® (ozanimod) Patient Card

(For women of childbearing potential)

Bristol Myers Squibb®

2084-IL-2500006

This card and its content have been approved by the Ministry of Health in June 2025

Patient Information

If used during pregnancy, ZEPOSIA® (ozanimod) can harm the unborn baby. Potential risks include loss of the unborn baby and birth defects.

- Do not use ozanimod if you are pregnant or breast-feeding, or could become pregnant and are not using effective birth control.
- Before starting treatment with ozanimod:
  1. Your prescriber will explain the potential risks to an unborn baby if you become pregnant while taking ozanimod and will regularly inform you how to minimize the risks.
  2. You must use effective birth control while taking ozanimod and for 3 months after you stop taking ozanimod.
  3. You must have a negative pregnancy test verified by your prescriber and repeated at suitable intervals.

- If you become pregnant while on treatment, ozanimod must be stopped. Your doctor will advise you of the harmful effects to the baby associated with ozanimod treatment and ultrasound exams should be performed.

- You should stop taking ozanimod 3 months before planning a pregnancy.

- If you stop taking ozanimod, tell your doctor right away if your disease symptoms get worse as there is a possibility that the disease may return.

- Tell your doctor right away if you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby.

Please see the back of this Patient Card for your prescriber's contact information.

For more information about the effects and side effects of ozanimod, please refer to the Patient Information Leaflet for ozanimod.

For more information please contact your doctor or pharmacist and refer to the Patient Information Leaflet. You can report side effects by using the online form for reporting adverse events on the home page of the Ministry of health website: www.health.gov.il or by entering the following link: https://sideeffects.health.gov.il

To obtain additional copies of this card, please contact Bristol-Myers Squibb by phone: 03-5231021 or fax: 03-9226896 or email: Office_IL@bms.com

Bristol Myers Squibb®

2084-IL-2500006